[go: up one dir, main page]

WO2008121666A1 - Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone - Google Patents

Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone Download PDF

Info

Publication number
WO2008121666A1
WO2008121666A1 PCT/US2008/058341 US2008058341W WO2008121666A1 WO 2008121666 A1 WO2008121666 A1 WO 2008121666A1 US 2008058341 W US2008058341 W US 2008058341W WO 2008121666 A1 WO2008121666 A1 WO 2008121666A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
thiophene
bromo
propoxy
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/058341
Other languages
French (fr)
Inventor
Ann Marie Gelormini
Adam W. Sledeski
John Joseph Shay, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of WO2008121666A1 publication Critical patent/WO2008121666A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • This invention is directed to the use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester as an intermediate in preparing the tryptase inhibitor [4- (5 -aminomethyl-2-fluoro-phenyl)-piperidin- 1 -yl]-(4-bromo-3 -methyl-5 -propoxy-thiophen-2- yl)-methanone.
  • WO2001/13811 discloses compounds including [(benzylamine)-piperidin-l-yl] (aryl or heteroaryl)methanone as tryptase inhibitors, and describes potential uses for such compounds due to tryptase being implicated in a variety of biological processes, including degradation of vasodilating and bronchorelaxing neuropeptides (Caughey, et al., J. Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther., 1988, 248, pages 947- 951; and Tarn, et al., Am. J. Respir. Cell MoI. Biol, 1990, 3, pages 27-32) and modulation of bronchial responsiveness to histamine (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175- 179).
  • WO2005/097780 more particularly discloses the (benzylamine)-piperidin-l-yl thienylmethanone compound of formula A ([4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-l- yl]-(4-bromo-3 -methyl-5 -propoxy-thiophen-2-yl)-methanone), its preparation, and use for treating disease states capable of being modulated by the inhibition of tryptase.
  • WO2005/097780 also discloses that the compound of the formula A is prepared through the coupling of the following compounds 16 and 10, and subsequent deprotection of the coupled product as follows
  • the invention is directed to the method of preparing the tryptase inhibitor [4-(5-aminomethyl- 2-fluoro-phenyl)-piperidin- 1 -yl] -(4-bromo-3 -methyl-5 -propoxy-thiophen-2-yl)-methanone comprising amidization coupling 4-bromo-3 -methyl-5 -propoxythiophene-2-carboxylic acid 2,5- dioxo-pyrrolidin-1-yl ester with 2,2,2-trifluoro-N-(4-fluoro-3-piperidin-4-yl-benzyl)- acetamide hydrochloride and strong base or tertiary amine base in alcohol solvent to yield 2,2,2-trifluoro-N- ⁇ 3-[l-(4-Bromo-3-methyl-5-propoxy-thiophene-2-carbonyl)- piperidin-4-yl]-4-fluoro-benzyl ⁇ -acetamide; and deprotecting 2,
  • Alkali metal means lithium, sodium, potassium or cesium.
  • Alkali metal propoxide salt means the salt form by the treatment of propanol with a strong base such as Cs 2 CO 3 , alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or alkylmetal such as alkyllithium, alkylpotassium, alkylsodium and alkylmagnesium wherein the alkyl is Ci_ 5 alkyl, more preferably butyl, i.e., CsOPr, NaOPr, LiOPr or KOPr.
  • a strong base such as Cs 2 CO 3
  • alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA)
  • alkylmetal such as alkyllithium, alkylpotassium, alkylsodium and alkylmagnesium wherein the alkyl is Ci_ 5 alkyl, more preferably butyl, i.
  • brominating agent means a bromine source such as Br 2 or NBS.
  • Copper catalyst means a copper catalyst capable of effecting an Ullmann coupling is selected from the group consisting of CuSCN, CuBr, CuI, CuCl, CuBF 4 , CuPF 6 , CuOTf, CuPF 6 , CuBr 2 , CuCl 2 , and Cu 2 O.
  • Coupling co-solvent means an additional inert organic solvent such as THF, toluene, 2- methylTHF, or dimethoxyethane that could be combined with the propanol coupling solvent.
  • Esterifying means the conversion of the carboxylic group to its corresponding ester.
  • Coupling agent means a compound useful for effecting an esterification selected from the group consisting of CDI, DCC, PFP, HOBT and HBTU, and the like.
  • Hydrolyzing co-solvent means an inert polar organic solvent such as an ether such as 1 ,4-Dioxane, t-butyl methyl ether (TBME), isopropyl ethyl ether and diethyl ether.
  • Baseic hydrolyzing means using alkali metal hydroxides such as lithium, sodium or potassium hydroxides, or alkaline earth hydroxide to effect the hydrolysis.
  • Iodinating agent means I 2 , diiodoethylene, ICl, or NBI.
  • Iodinating means reacting with an iodinating agent in the presence of a strong base.
  • Non-protic polar solvent means a solvent such ether, t-butyl methyl ether (TBME), isopropyl ethyl ether, THF, 1,4-dioxane or 1,3-dioxolane, or the like.
  • Hydrocarbon solvent means a solvent such as toluene, xylene or heptane, or the like.
  • Halohydrocarbon solvent means a C 3 _ 5 halo, preferably fluoro or chloro, substituted hydrocarbon such as chloroform or methylene chloride.
  • “Inert solvent” means an non-protic polar solvent, hydrocarbon solvent, halohydrocarbon solvent, nitrile solvent such as acetonitrile, or organic acid solvent such as acetic or propanoic acid.
  • “Strong base” means an alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or alkylmetal base such as alkyllithium, alkylpotassium, alkylsodium and alkylmagnesium wherein the alkyl is Ci_ 6 alicyclic (straight, branched or cyclic alkyl), more preferably butyl.
  • Ci_5 organic base wherein the nitrogen thereof does not bear a hydrogen, such as triethylamine.
  • the iodinating is effected in THF.
  • the strong base used in the iodinating is LDA.
  • the iodination agent is I 2 .
  • the iodinating is effected at about -8O 0 C to about O 0 C.
  • the alkali metal propoxide salt is NaOPr.
  • the copper catalyst is CuI.
  • the coupling is carried out with heating at about 70 0 C to about 120 0 C depending on the solvent used and pressure utilized.
  • the solvent used for carrying out the coupling with CO 2 is effected in THF.
  • the strong base used for coupling with CO 2 is n-BuLi.
  • the coupling with CO 2 is carried out at a temperature below -14°C, more particular from about - 22°C to about -14°C.
  • the solvent for the esterifying is dichloromethane.
  • the coupling agent used for the esterifying is ⁇ iV-carbonyldiimidazole. In another particular embodiment of the method according to the present invention, the esterifying is carried out at about rt.
  • the inert solvent for bromination is halohydro carbon; more particularly dichloromethane.
  • the brominating is effected from about O 0 C to about 100 0 C.
  • the brominating agent is Br 2 .
  • the alcohol solvent for the amidization coupling is ethanol.
  • the amidization coupling is effected at about rt to about 3O 0 C.
  • the base for the amidization coupling is triethylamine.
  • the deprotecting is effected using aqueous base; aqueous NaOH.
  • the deprotecting is effected from about 5 0 C to about 3O 0 C.
  • iodine (454 g, 1.3 equiv) is dissolved in THF (1.65 L), stirred at rt for 20 min to ensure complete dissolution and cooled to -20 0 C. By the time the solution had cooled to -10 0 C, iodine began to precipitate.
  • the anion solution is brought to 0 0 C and cannulated over 40 minutes into a solution of the iodide, adjusting the rate as necessary to keep the reaction at or below -15°C.
  • the mixture is allowed to warm to 10 0 C over 2h.
  • the reaction is diluted with MTBE (1.0 L) and the reaction is quenched with 1 A sat'd ammonium chloride (500 mL).
  • the organic layer is washed with 0.5 N sodium thiosulfate (2 x 750 mL), 2 x 1 L water (2 x IL) and brine (200 mL).
  • the organic layers are allowed to sit in the separator for 4h and any separated water is drawn-off.
  • the organic layers are concentrated by rotary evaporation at 30 0 C and 175 mbar to 1.2 L. Essentially no product is detected by HPLC in either the aqueous phase or distillates. A small and unquantif ⁇ able amount of unreacted 3-methylthiophene is lost to the washes and evaporation. Based on recovered starting material, off-isomer formation, and the absence of product in either washings or rotovap distillates, the yield for this reaction is calculated as 73% for the purposes of estimating the reagents for the Ullmann coupling.
  • Example 2 In a 3 L 3N flask equipped with a reflux condenser atop a Dean-Stark trap, overhead stirring, headspace thermocouple, and nitrogen in/outlets, the 1.2 L of solution from Example 1 is combined with n-propanol. (1 L). The mixture is heated to reflux and distillates drawn-off and partially replaced with n-propanol (ca 1.2 L removed and 500 mL n-propanol added) until the head temperature reached 96 0 C. The mixture is cooled to 50 0 C and sodium t-butoxide (192 g, 2 mol, ca 2 equiv) is added as a solid causing an exotherm to ca 75 0 C.
  • sodium t-butoxide 192 g, 2 mol, ca 2 equiv
  • the mix is held between 75 and 85°C until all solids dissolved.
  • the reaction mixture is re-cooled to 50 0 C and freshly prepared copper iodide 1 (100 mmol, 19 g) in n-propanol (50 ml) is added as a slurry..
  • the mixture is heated to 95 0 C.
  • An HPLC assay at 30 minutes after the reaction temperature is reached showed the reaction to be complete.
  • the mixture is diluted with heptane (1 L). Celite (190 g) is added and the resulting slurry is stirred for 60 min while cooling to rt. The mixture is filtered and the cake washed with heptane (500 mL).
  • the combined filtrates and washings are washed with 5% aqueous disodium EDTA, (3 x 500 mL), water (3 x 500 mL) and brine (500 mL), to give a very dark organic layer which is concentrated to ⁇ 200 mL (170 mbar ,60 0 C) to give 159 g of a dark brown liquid that is 51A% desired compound by 1 H NMR.
  • the major impurities are heptane, ethylbenzene (from commercial LDA) and 2-iodo- 3 -methy lthiophene .
  • N-hydroxysuccinimide (68.3 g, 1.4 equiv) and dichloromethane (700 mL) and stirred at rt. to give a brown solution and a 3°C endotherm on mixing.
  • the cooling bath is filled with rt water and is present only to mitigate a slight exotherm.
  • JV,jV-carbonyldiimidazole (104 g, 1.1 equiv) is added as a solid in four 26.0 g portions spaced 10 min apart. Each addition is followed by a 2-3°C exotherm and gentle gas evolution. After the final addition, the mixture is stirred a rt for 3h or overnight.
  • the mixture is quenched with half saturated ammonium chloride (200 mL) and is washed with water (3 x 150 mL) and brine (150 mL).
  • the product is isolated by solvent exchange with heptane at 170 mbar and 30 0 C. After solid formed, the mixture is cooled to rt and then to 5°C to give a bright yellow solid which is isolated by filtration through cloth, washed with heptane, air dried on a frit for 20 min and further dried (30 0 C, 1.5 in Hg) to give 3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester (104 g, 83%).
  • the organic phases are dried (Na 2 SO 4 ) and concentrated (30 0 C, 125 mbar) to give a brown solid which is re-dissolved in DCM (700 mL) and treated at 5°C with bromine (4 mL, 78 mmol, 0.3 equiv) in heptane (20 mL) to complete the reaction.
  • the organic phase is partitioned against 250 mL 1 N aq sodium thiosulfate (250 mL) and washed with water (2 x 250 mL) and brine (250 mL).
  • the solvent volume is reduced (30 0 C, 125 mbar) to 300 mL and 400 mL heptane is added (effecting some crystallization).
  • the reaction mixture is stirred for 18 h, and then partitioned between 1.5 L of water and 1.5 L of TBME.
  • the organic phase is washed with water (2 x 0.5 L), 1 N aq HCl (0.5 L) and brine (0.2 L).
  • the solution is cooled to 7 0 C, and 194 mL of aq. 50% NaOH is added causing an exotherm that warms the mixture to 24 0 C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention is directed to a five step regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid compound of formula 16 comprising the steps of acetalating 3-methyl-thiophene-2-carbaldehyde in an alcohol solvent; iodinating the acetalated 3-methyl-thiophene-2-carbaldehyde in an non-protic polar or hydrocarbon solvent to yield the corresponding iodinated and acetalated 3-methyl-thiophene-2-carbaldehyde product; treating the iodinated and acetalated product with water to yield the corresponding 5-iodo-3-methyl-thiophene-2-carbaldehyde; oxidizing the 5-iodo-3-methyl-thiophene-2-carbaldehyde to the corresponding 5-iodo-3-methyl-thiophene-2-carboxylic acid in ketone solvent; Ullmann coupling of the 5-iodo-3-methyl-thiophene-2-carboxylic acid with alkali metal propoxide salt using a copper catalyst in propanol to yield 3-methyl-5-propoxy-thiophene-2-carboxylic acid; esterifying 3-methyl-5-propoxy-thiophene-2-carboxylic acid to yield the corresponding alkyl 3-methyl-5-propoxy-thiophene-2-carboxylate; brominating the 3-methyl-5-propoxy-thiophene-2-carboxylic acid to yield the corresponding alkyl 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylate; and basic hydrolyzing the alkyl 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylate with base to yield 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid.

Description

USE OF 4-BROMO-3-METHYL-5-PROPOXYTHIOPHENE-2-C ARBOXYLIC ACID
2,5-DIOXO-PYRROLIDIN-l-YL ESTER FOR PREPARING THE TRYPTASE
INHIBITOR [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-l-YL]-(4-
BROMO-S-METHYL-S-PROPOXY-THIOPHEN-I-YL)-METHANONE
FIELD OF THE INVENTION
This invention is directed to the use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester as an intermediate in preparing the tryptase inhibitor [4- (5 -aminomethyl-2-fluoro-phenyl)-piperidin- 1 -yl]-(4-bromo-3 -methyl-5 -propoxy-thiophen-2- yl)-methanone.
BACKGROUND OF THE INVENTION
WO2001/13811 discloses compounds including [(benzylamine)-piperidin-l-yl] (aryl or heteroaryl)methanone as tryptase inhibitors, and describes potential uses for such compounds due to tryptase being implicated in a variety of biological processes, including degradation of vasodilating and bronchorelaxing neuropeptides (Caughey, et al., J. Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther., 1988, 248, pages 947- 951; and Tarn, et al., Am. J. Respir. Cell MoI. Biol, 1990, 3, pages 27-32) and modulation of bronchial responsiveness to histamine (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175- 179).
WO2005/097780 more particularly discloses the (benzylamine)-piperidin-l-yl thienylmethanone compound of formula A ([4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-l- yl]-(4-bromo-3 -methyl-5 -propoxy-thiophen-2-yl)-methanone),
Figure imgf000003_0001
its preparation, and use for treating disease states capable of being modulated by the inhibition of tryptase. WO2005/097780 also discloses that the compound of the formula A is prepared through the coupling of the following compounds 16 and 10, and subsequent deprotection of the coupled product as follows
Figure imgf000003_0002
Intermediate compound 16 was prepared according to following multistep preparation
Figure imgf000004_0001
While the aforesaid procedure works to prepare intermediate 16, however it utilizes a number of steps, employs acyclic intermediates exhibiting unpleasant odor characteristics, and doesn't start from a readily available thienyl starting material. The process also requires an extra step in the conversion of the ester moiety in compound 15 to the corresponding acid moiety in compound 16, i.e., a manipulation of carboxy functional group in intermediates leading to compound 16.
The invention is directed to the method of preparing the tryptase inhibitor [4-(5-aminomethyl- 2-fluoro-phenyl)-piperidin- 1 -yl] -(4-bromo-3 -methyl-5 -propoxy-thiophen-2-yl)-methanone comprising amidization coupling 4-bromo-3 -methyl-5 -propoxythiophene-2-carboxylic acid 2,5- dioxo-pyrrolidin-1-yl ester with 2,2,2-trifluoro-N-(4-fluoro-3-piperidin-4-yl-benzyl)- acetamide hydrochloride and strong base or tertiary amine base in alcohol solvent to yield 2,2,2-trifluoro-N-{3-[l-(4-Bromo-3-methyl-5-propoxy-thiophene-2-carbonyl)- piperidin-4-yl]-4-fluoro-benzyl} -acetamide; and deprotecting 2,2,2-trifluoro-N-{3-[l-(4-Bromo-3-methyl-5-propoxy-thiophene-2- carbonyl)-piperidin-4-yl]-4-fluoro-benzyl} -acetamide with base to yield [4-(5- -A-
aminomethyl-2-fluoro-phenyl)-piperidin- 1 -yl] -(4-bromo-3 -methyl-5 -propoxy- thiophen-2-yl)-methanone.
DETAILED DESCRIPTION OF THE INVENTION The present invention will be better appreciated by reference to the following Detailed Description.
Definitions
As used above, and throughout the description of the invention including the appended claims, the following abbreviations and terms, unless otherwise indicated, are understood to have the following meanings:
"Alkali metal" means lithium, sodium, potassium or cesium.
"Alkali metal propoxide salt" means the salt form by the treatment of propanol with a strong base such as Cs2CO3, alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or alkylmetal such as alkyllithium, alkylpotassium, alkylsodium and alkylmagnesium wherein the alkyl is Ci_5 alkyl, more preferably butyl, i.e., CsOPr, NaOPr, LiOPr or KOPr.
"Amidization coupling"means coupling to form an amide.
"Brominating agent" means a bromine source such as Br2 or NBS.
"Copper catalyst" means a copper catalyst capable of effecting an Ullmann coupling is selected from the group consisting of CuSCN, CuBr, CuI, CuCl, CuBF4, CuPF6, CuOTf, CuPF6, CuBr2, CuCl2, and Cu2O.
"Coupling co-solvent" means an additional inert organic solvent such as THF, toluene, 2- methylTHF, or dimethoxyethane that could be combined with the propanol coupling solvent.
"Esterifying" means the conversion of the carboxylic group to its corresponding ester.
"Coupling agent" means a compound useful for effecting an esterification selected from the group consisting of CDI, DCC, PFP, HOBT and HBTU, and the like. "Hydrolyzing co-solvent": means an inert polar organic solvent such as an ether such as 1 ,4-Dioxane, t-butyl methyl ether (TBME), isopropyl ethyl ether and diethyl ether. "Basic hydrolyzing" means using alkali metal hydroxides such as lithium, sodium or potassium hydroxides, or alkaline earth hydroxide to effect the hydrolysis.
"Iodinating agent" means I2, diiodoethylene, ICl, or NBI.
"Iodinating" means reacting with an iodinating agent in the presence of a strong base.
"Non-protic polar solvent" means a solvent such ether, t-butyl methyl ether (TBME), isopropyl ethyl ether, THF, 1,4-dioxane or 1,3-dioxolane, or the like.
"Hydrocarbon solvent" means a solvent such as toluene, xylene or heptane, or the like.
"Halohydrocarbon solvent" means a C3_5 halo, preferably fluoro or chloro, substituted hydrocarbon such as chloroform or methylene chloride.
"Inert solvent" means an non-protic polar solvent, hydrocarbon solvent, halohydrocarbon solvent, nitrile solvent such as acetonitrile, or organic acid solvent such as acetic or propanoic acid.
"Strong base" means an alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or alkylmetal base such as alkyllithium, alkylpotassium, alkylsodium and alkylmagnesium wherein the alkyl is Ci_6 alicyclic (straight, branched or cyclic alkyl), more preferably butyl.
"Tertiary amine base" means a Ci_5 organic base wherein the nitrogen thereof does not bear a hydrogen, such as triethylamine.
Particular Embodiments
In a particular embodiment of the method according to the present invention, the iodinating is effected in THF.
In another particular embodiment of the method according to the present invention, the strong base used in the iodinating is LDA. In another particular embodiment of the method according to the present invention, the iodination agent is I2.
In another particular embodiment of the method according to the present invention, the iodinating is effected at about -8O0C to about O0C.
In another particular embodiment of the method according to the present invention, the alkali metal propoxide salt is NaOPr.
In another particular embodiment of the method according to the present invention, the copper catalyst is CuI.
In another particular embodiment of the method according to the present invention, the coupling is carried out with heating at about 700C to about 1200C depending on the solvent used and pressure utilized.
In another particular embodiment of the method according to the present invention, the solvent used for carrying out the coupling with CO2 is effected in THF.
In another particular embodiment of the method according to the present invention, the strong base used for coupling with CO2 is n-BuLi.
In another particular embodiment of the method according to the present invention, the coupling with CO2 is carried out at a temperature below -14°C, more particular from about - 22°C to about -14°C.
In another particular embodiment of the method according to the present invention, the solvent for the esterifying is dichloromethane.
In another particular embodiment of the method according to the present invention, the coupling agent used for the esterifying is Λ^iV-carbonyldiimidazole. In another particular embodiment of the method according to the present invention, the esterifying is carried out at about rt.
In another particular embodiment of the method according to the present invention, the inert solvent for bromination is halohydro carbon; more particularly dichloromethane.
In another particular embodiment of the method according to the present invention, the brominating is effected from about O0C to about 1000C.
In another particular embodiment of the method according to the present invention, the brominating agent is Br2.
In another particular embodiment of the method according to the present invention, the alcohol solvent for the amidization coupling is ethanol.
In another particular embodiment of the method according to the present invention, the amidization coupling is effected at about rt to about 3O0C.
In another particular embodiment of the method according to the present invention, the base for the amidization coupling is triethylamine.
In another particular embodiment of the method according to the present invention, the deprotecting is effected using aqueous base; aqueous NaOH.
In another particular embodiment of the method according to the present invention, the deprotecting is effected from about 50C to about 3O0C.
Examples
Preparatory Details The starting materials used herein may be purchased or prepared by the application or adaptation of known methods or their obvious chemical equivalents. The present invention may be better understood by reference to the following non-limiting Examples, which are exemplary of the invention. The following examples are presented in order to more fully illustrate a particular embodiment of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
In the nuclear magnetic resonance spectra (NMR), reported infra, the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: br = broad, dd = double doublet, s = singlet; m = multiplet.
The synthesis of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo- pyrrolidin-1-yl ester as is described in the examples that follow is represented by the following Scheme I.
Scheme I
Figure imgf000009_0001
Example 1 2-iodo-4-methyl-thiophene
A 3 L 4-Neck flask, equipped with overhead stirring, rubber septum, thermocouple and nitrogen inlet/outlet is charged with 3-methylthiophene (135 mL, 1.38 mol) and THF (1 L). The mixture is cooled to -200C and LDA (800 mL of Aldrich 2.5 M solution in THF/Heptane/ethylbenzene) is added via 12 gauge cannula over 35 minutes, adjusting the addition rate and cooling as necessary to maintain the reaction temp between -25°C and -15°C. The mixture is allowed to stir for 30 min after conclusion of addition, keeping the temperature below 0 0C.
In a separate 5 L flask equipped with overhead stirring, cooling bath, nitrogen flow and thermocouple, iodine (454 g, 1.3 equiv) is dissolved in THF (1.65 L), stirred at rt for 20 min to ensure complete dissolution and cooled to -200C. By the time the solution had cooled to -100C, iodine began to precipitate.
The anion solution is brought to 00C and cannulated over 40 minutes into a solution of the iodide, adjusting the rate as necessary to keep the reaction at or below -15°C. At the conclusion of the addition, the mixture is allowed to warm to 100C over 2h. The reaction is diluted with MTBE (1.0 L) and the reaction is quenched with 1A sat'd ammonium chloride (500 mL). The organic layer is washed with 0.5 N sodium thiosulfate (2 x 750 mL), 2 x 1 L water (2 x IL) and brine (200 mL). The organic layers are allowed to sit in the separator for 4h and any separated water is drawn-off. The organic layers are concentrated by rotary evaporation at 300C and 175 mbar to 1.2 L. Essentially no product is detected by HPLC in either the aqueous phase or distillates. A small and unquantifϊable amount of unreacted 3-methylthiophene is lost to the washes and evaporation. Based on recovered starting material, off-isomer formation, and the absence of product in either washings or rotovap distillates, the yield for this reaction is calculated as 73% for the purposes of estimating the reagents for the Ullmann coupling.
1H NMR (CDCl3, δ) 7.05 (IH, tight m), (6.91 (IH, tight m), (2.21, 3H, s)
Example 2 4-Methyl-2-propoxythiophene
In a 3 L 3N flask equipped with a reflux condenser atop a Dean-Stark trap, overhead stirring, headspace thermocouple, and nitrogen in/outlets, the 1.2 L of solution from Example 1 is combined with n-propanol. (1 L). The mixture is heated to reflux and distillates drawn-off and partially replaced with n-propanol (ca 1.2 L removed and 500 mL n-propanol added) until the head temperature reached 96 0C. The mixture is cooled to 500C and sodium t-butoxide (192 g, 2 mol, ca 2 equiv) is added as a solid causing an exotherm to ca 75 0C. The mix is held between 75 and 85°C until all solids dissolved. The reaction mixture is re-cooled to 500C and freshly prepared copper iodide1 (100 mmol, 19 g) in n-propanol (50 ml) is added as a slurry.. The mixture is heated to 95 0C. An HPLC assay at 30 minutes after the reaction temperature is reached showed the reaction to be complete. The mixture is diluted with heptane (1 L). Celite (190 g) is added and the resulting slurry is stirred for 60 min while cooling to rt. The mixture is filtered and the cake washed with heptane (500 mL). The combined filtrates and washings are washed with 5% aqueous disodium EDTA, (3 x 500 mL), water (3 x 500 mL) and brine (500 mL), to give a very dark organic layer which is concentrated to <200 mL (170 mbar ,60 0C) to give 159 g of a dark brown liquid that is 51A% desired compound by 1H NMR. The major impurities are heptane, ethylbenzene (from commercial LDA) and 2-iodo- 3 -methy lthiophene .
1H NMR (CDCl3, δ) 6.18 (IH, d); 6.02 (IH, d); 3.98 (2H, t); 2.15 (3H, S); 2.80 (2H, m); 1.05 (3H, t).
Example 3 3-Methyl-5-propoxythiophene-2-carboxylic acid
Crude 4-methyl-2-propoxythiophene of example 2 (calculated 79 g, 506 mmol) is transferred to a 2 L 3N flask equipped with overhead stirring, thermocouple, nitrogen in/outlets, a pressure-equalized dropping funnel and a rubber septum and diluted with 600 mL THF. The mix is cooled to -22°C and 2.5 M n-butyllithium (283 mL, 1.4 equiv) in hexanes is added rapidly dropwise via addition funnel over 16 min and the temp range -22 to -14°C, stabilizing around -21°C. After 30 min, keeping the temperature below -15°C, a sample of the reaction mixture is assayed (via a D2O quench) to show ca 96% lithiation. Carbon dioxide is bubbled into the mixture, controlling the gas flow rate in order to keep the reaction temperature below -15°C. Addition of CO2 is continued until the exotherm subsides and the reaction temperature begins to drop. The reaction is quenched with 0.5 Naq sodium hydroxide (600 mL) and celite (50 g) is added. The mixture is stirred for 30 min and filtered through cloth. The cake is washed with 0.5 N sodium hydroxide (30 mL). The combined filtrates and washings gives a dark brown solution which is washed with heptane (3 x 200 mL). The pH of the aqueous phase is adjusted to ca 6.8, at which point a sticky brown/black tar is formed. The solution is filtered through cloth, giving a pale brown filtrate. pH adjustment is continued to 4.5, to give
1 Copper iodide is freshly ground in a mortar and pestle and sonicated for 5 minutes as a slurry in n-propanol. a copious brown precipitate which is filtered through cloth, washed with ice water (100 mL), air-dried on the frit and vacuum oven dried (12 h, 300C, 1.3 mbar) to give 3-methyl-5- propoxythiophene-2-carboxylic acid as a beige solid (81.1 g, 80%).
1H NMR (CDCl3, δ) 6.12 (IH, s); 4.02 (3H, t); 2.49 (3H, s); 1.82 (2H, m); 1.05 (3H, t).
Example 4 3-Methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester
A 2 L 3 N flask with overhead stirring, cooling bath, thermocouple and nitrogen inlet/ outlet is charged with 3-methyl-5-propoxythiophene-2-carboxylic acid (85.0 g, 424 mmol),
N-hydroxysuccinimide (68.3 g, 1.4 equiv) and dichloromethane (700 mL) and stirred at rt. to give a brown solution and a 3°C endotherm on mixing. The cooling bath is filled with rt water and is present only to mitigate a slight exotherm. JV,jV-carbonyldiimidazole (104 g, 1.1 equiv) is added as a solid in four 26.0 g portions spaced 10 min apart. Each addition is followed by a 2-3°C exotherm and gentle gas evolution. After the final addition, the mixture is stirred a rt for 3h or overnight. The mixture is quenched with half saturated ammonium chloride (200 mL) and is washed with water (3 x 150 mL) and brine (150 mL). The product is isolated by solvent exchange with heptane at 170 mbar and 300C. After solid formed, the mixture is cooled to rt and then to 5°C to give a bright yellow solid which is isolated by filtration through cloth, washed with heptane, air dried on a frit for 20 min and further dried (30 0C, 1.5 in Hg) to give 3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester (104 g, 83%).
1H NMR (CDCl3, δ) 6.20 (IH, s); 4.05 (3H, t); 2.95 (4H, s); 2.51 (3H, s); 1.82 (2H, m); 1.05 (3H, t).
Example 5 4-Bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin- l-yl ester
A 2 L 3 N round bottom flask equipped with thermocouple, ice bath and overhead stirring is charged with 3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester (81 g, 273 mmol), isopropanol (500 mL) and DCM (350 mL) to give a very thin slurry. The mixture is cooled to <5°C and a solution of bromine (22 mL, 328 mmol, 1.2 equiv) in heptane (80 niL) is added dropwise over the temperature range 4 to 11 °C. The thin slurry thinned still further but the mixture did not completely homogenize. The solution is added over 19 min and the reaction assayed as complete. The reaction is diluted with DCM (600 mL) and quenched with 1 N sodium thiosulfate (250 mL). The organic layer is washed with water (2 x 350 mL). HPLC assay at this point showed ca 6.3% unreacted starting material, presumably due to coating of glassware by starting material rendering it undetectable to a solution assay. The organic phases are dried (Na2SO4) and concentrated (30 0C, 125 mbar) to give a brown solid which is re-dissolved in DCM (700 mL) and treated at 5°C with bromine (4 mL, 78 mmol, 0.3 equiv) in heptane (20 mL) to complete the reaction. The organic phase is partitioned against 250 mL 1 N aq sodium thiosulfate (250 mL) and washed with water (2 x 250 mL) and brine (250 mL). The solvent volume is reduced (30 0C, 125 mbar) to 300 mL and 400 mL heptane is added (effecting some crystallization). The mixture is concentrated to dryness by rotary evaporation to give 104 g of a brown solid. The crude product is recrystallized from refluxing IPA (500 mL), and dried (40 0C, 1.5 in Hg) to give 93 g of 4- bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-l-yl ester as a tan solid (91%).
1H NMR (CDCl3, δ) 4.19 (2H, t); 2.92 (4H, s); 3.59 (3H, s); 1.95 (2H, m); 1.08 (3H, t)
Example 6 [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-l-yl]-(4-bromo-3-methyl-5 -propoxy-thiophen-2-yl)-methanone
A 5-L, 3-neck round-bottom flask is charged with 2,2,2-trifluoro-N-(4-fluoro-3-piperidin-4-yl- benzyl)-acetamide hydrochloride (176.7 g, 0.518 mol) and 1.51 L of absolute EtOH. The mixture is stirred and triethylamine (215 mL, 1.55 mol) added. The mixture is stirred for 3 min and then 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin- l-yl ester (194 g, 0.516 mol) is added causing an exotherm that warms the mixture to 26 0C. The reaction mixture is stirred for 18 h, and then partitioned between 1.5 L of water and 1.5 L of TBME. The organic phase is washed with water (2 x 0.5 L), 1 N aq HCl (0.5 L) and brine (0.2 L). The dark amber organic phase is passed through a short pad of SiO2 (h=0.5", φ=3.5"), eluting with 0.3 L of EtOAc. No significant color reduction occurs. The solution is cooled to 70C, and 194 mL of aq. 50% NaOH is added causing an exotherm that warms the mixture to 240C. After 3 h, the mixture is washed with water (2 x 1 L, 1 x 0.8 L), brine (0.5 L) and then the organic phase is dried over sodium sulfate. The solution is cooled to 130C, and 4 N HCl in 1,4-dioxane (135 mL, 0.54 mol) is added dropwise. The mixture is stirred for 3 h, and then the product is isolated by filtration (quite slow), washed with MTBE and air-dried for 15 h to afford 130.2 g (50%) of [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-l-yl]-(4-bromo-3- methyl-5-propoxy-thiophen-2-yl)-methanone as a light-beige solid.

Claims

We Claim:
1. The process for preparing [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin- 1 -yl]-(4- bromo-3 -methyl-5 -propoxy-thiophen-2-yl)-methanone comprising amidization coupling 4-bromo-3 -methyl-5 -propoxythiophene-2-carboxylic acid 2,5- dioxo-pyrrolidin-1-yl ester with 2,2,2-trifluoro-N-(4-fluoro-3-piperidin-4-yl-benzyl)- acetamide hydrochloride and strong base or tertiary amine base in alcohol solvent to yield 2,2,2-trifluoro-N-{3-[l-(4-Bromo-3-methyl-5-propoxy-thiophene-2-carbonyl)- piperidin-4-yl]-4-fluoro-benzyl} -acetamide; and deprotecting 2,2,2-trifluoro-N-{3-[l-(4-Bromo-3-methyl-5-propoxy-thiophene-2- carbonyl)-piperidin-4-yl]-4-fluoro-benzyl} -acetamide with base to yield [4-(5- aminomethyl-2-fluoro-phenyl)-piperidin- 1 -yl] -(4-bromo-3 -methyl-5 -propoxy- thiophen-2-yl)-methanone.
2. The method according to claim 1 wherein the alcohol solvent for the amidization coupling is ethanol.
3. The method according to claim 1 wherein the amidization coupling is effected at about rt to about 3O0C.
4. The method according to claim 1 wherein the base for the amidization coupling is triethylamine.
5. The method according to claim 1 wherein the base for the deprotecting is effected using aqueous base; aqueous NaOH.
6. The method according to claim 1 wherein the base for the deprotecting is effected from about 50C to about 3O0C.
PCT/US2008/058341 2007-03-29 2008-03-27 Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone Ceased WO2008121666A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90884407P 2007-03-29 2007-03-29
US60/908,844 2007-03-29

Publications (1)

Publication Number Publication Date
WO2008121666A1 true WO2008121666A1 (en) 2008-10-09

Family

ID=39535396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/058341 Ceased WO2008121666A1 (en) 2007-03-29 2008-03-27 Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone

Country Status (3)

Country Link
AR (1) AR065858A1 (en)
TW (1) TW200904811A (en)
WO (1) WO2008121666A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011124930A1 (en) 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
WO2011158044A2 (en) 2010-06-17 2011-12-22 Respivert Limited Respiratory formulations and compounds for use therein
JP2012500794A (en) * 2008-08-22 2012-01-12 サノフイ [4- (5-Aminomethyl-2-fluoro-phenyl) -piperidin-1-yl]-[7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy- as mast cell tryptase inhibitor 1H-Indol-3-yl] -methanone
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097780A1 (en) * 2004-03-26 2005-10-20 Aventis Pharmaceuticals Inc. [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097780A1 (en) * 2004-03-26 2005-10-20 Aventis Pharmaceuticals Inc. [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINE, GARY W. ET AL: "The aminolysis of N-hydroxysuccinimide esters. A structure-reactivity study", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 109(10), 3087-91 CODEN: JACSAT; ISSN: 0002-7863, 1987, XP002486129 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500794A (en) * 2008-08-22 2012-01-12 サノフイ [4- (5-Aminomethyl-2-fluoro-phenyl) -piperidin-1-yl]-[7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy- as mast cell tryptase inhibitor 1H-Indol-3-yl] -methanone
US20120283445A1 (en) * 2008-08-22 2012-11-08 Sanofi [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
US8497379B2 (en) * 2008-08-22 2013-07-30 Sanofi Method and intermediates for the preparation of 2,2,2-trifluoro-N-(4-fluoro-3-pyridin-4-yl-benzyl)-acetamide hydrochloride
CN103508936A (en) * 2008-08-22 2014-01-15 赛诺菲-安万特 Intermediates for the preparation of indole benzylamine compounds
AU2009282884B2 (en) * 2008-08-22 2014-01-23 Sanofi [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors
WO2011124930A1 (en) 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
WO2011158044A2 (en) 2010-06-17 2011-12-22 Respivert Limited Respiratory formulations and compounds for use therein
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
US10358445B2 (en) 2010-06-17 2019-07-23 Respivert, Ltd. Respiratory formulations and compounds for use therein

Also Published As

Publication number Publication date
AR065858A1 (en) 2009-07-08
TW200904811A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
US8329905B2 (en) Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate
ES2211917T3 (en) IMIDAZOL DERIVATIVE
RU2682660C9 (en) Method of obtaining pde4 inhibitor
NO340366B1 (en) Process for the preparation of 3- (2- (1-benzothiophen-5-yl) ethoxy) propionic acid or salts thereof
CA2356838A1 (en) Imidazole compounds and medicinal use thereof
JP2011046751A (en) Synthesis of himbacine analog
KR20170023942A (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
WO2008121666A1 (en) Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone
CN116194450A (en) Process for preparing isoxazoline compounds and intermediates thereof
DE69306595T2 (en) REGIOSELECTIVE SYNTHESIS OF 4-CHLORINE-2-THIOPHENIC CARBONIC ACID
WO2008121669A1 (en) 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
RU2552350C2 (en) Method of biphenylimidazole compounds
WO2008109786A2 (en) Regio-selective ullmann synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
WO2020201975A2 (en) Novel process for the preparation of filgotinib and intermediates thereof
WO2008115912A1 (en) Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
CA2465686C (en) Process for the preparation of 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine)
NO326034B1 (en) Benzo [c] quinolizine derivatives, method of preparation and use thereof as 5 &lt;alfa&gt; reductase inhibitors
CN109485567B (en) Clean preparation method of 4-hydroxymethylthiazole and intermediate thereof
CN100389110C (en) A kind of method for preparing aromatic ring substituted isoxazoline compounds
CN105111229A (en) Synthetic method for silthiopham
JP4675234B2 (en) Intermediate for producing optically active quinolonecarboxylic acid derivative and process for producing the same
KR101723832B1 (en) Process for Preparing Ethyl-4-methyl-5-thiazolecarboxyate
JP3230723B2 (en) Method for producing 2- (furfurylthio) acetic acid derivative
CN106432109A (en) Preparation method of quizalofop-P-ethyl
JPS58201770A (en) Alpha-substituted-1,2-benzisoxazole-3-acetic acid ester, its acid addition salt and quaternary ammonium salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732887

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08732887

Country of ref document: EP

Kind code of ref document: A1